Page 44 - MDAnderson Memoria 2018

Listado de ensayos clínicos iniciados en 2017
List of clinical trials started in 2017
44
IMGN853-0403 (FORWARD1)
IMMUNOGEN, INC.
FORWARD1: “A Randomized, Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Adults with Folate Receptor α−positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Primary Fallopian Tube Cancer”
Dr. Antonio González
D0816C00014 (OReO)
AstraZeneca
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment
in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)
Dra. Raquel Bratos
E7080-A001-111
EISAI
A multicenter, open-label phase 1b/2 trial of levantinib (E7080) plus pembrolizumab in subjects with selected solid tumors
Dra. Raquel Bratos
MTRAP-2016-01
Mtrap, Inc
Safety and Performance of Metastatic Tumor Cell Trap Device in Patients with Advanced Ovarian Cancer
Dr. Javier de Santiago
C31005
TAKEDA (Millenium)
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy
Dra. Pilar López Criado
WO30070 (IMvigor)
ROCHE
Estudio de Fase III multicéntrico, randomizado, controlado con placebo de atezolizumab en monoterapia y en combinación con QT basada en platino en pacientes con carcinoma urotelial localmente avanzado o metastásico no tratado previamente
Phase III study, multicenter, randomized, placebo controlled with atezolizumab in monotherapy and combined with platinum based QT in patients with locally advanced or previously untreated metastatic urothelial carcinoma
Dr. Enrique Grande
CO-338-052 (TRITON2)
Clovis Oncology
A multicenter, open-label phase 2 study of rucaparib in patients with metastasic castration-resistant prostate cancer associated with homologous recombination deficiency
Dr. José Ángel Arranz
CO-338-063 (TRITON3)
Clovis Oncology
A multicenter, randomized, Phase 3 study of rucaparib versus physician`s choice as 2nd line treatment following androgen receptor directed therapy for patient with metastasic castration-resistant prostate cancer
Dr. José Ángel Arranz
B-701-U21
BioClin Therapeutics, Inc.
A Phase1b/2, Randomized,Double-Blind,Placebo- Controlled,Multicenter, Parallel-Group Study of B-701Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinomain Subjects who have Relapsed After,or are Refractory to Standard Therapy
Dra. Pilar López Criado